169 related articles for article (PubMed ID: 26463031)
1. [Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer].
Su W; Zhang S; Li C; Hao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2015 May; 37(5):379-82. PubMed ID: 26463031
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety analysis of paclitaxel, docetaxel and liposomal paclitaxel after neoadjuvant therapy in breast cancer.
Bi Z; Chen P; Liu YB; Zhao T; Sun X; Song XR; Wang YS
Breast Cancer Res Treat; 2020 Nov; 184(2):397-405. PubMed ID: 32776291
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer.
Li WP; Zhu T; Hu MX; Yang M; Ji F; Gao HF; Yang CQ; Zhang LL; Cheng MY; Xu FP; Wang K
Neoplasma; 2020 Nov; 67(6):1409-1415. PubMed ID: 32657611
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy of neoadjuvant chemotherapy FEC 100 and Docetaxel 75 versus AC and Docetaxel in locally advanced breast cancer: a randomized clinical study.
Dhanraj KM; Dubashi B; Gollapalli S; Kayal S; Cyriac SL
Med Oncol; 2015 Dec; 32(12):261. PubMed ID: 26520144
[TBL] [Abstract][Full Text] [Related]
7. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
8. [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Shen ZZ; Liu GY; Su FX; He PQ; Yang MT; Shi JY; Sheng Y; Zou Q; Li YF
Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):126-8. PubMed ID: 15946557
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
10. [Clinical comparative study of neoadjuvant chemotherapy outcome in locally advanced breast cancer: docetaxel versus paclitaxel plus pirarubicin hydrochloride and cyclophosphamide].
Su J; Li MQ; Xu H; Hu D
Zhonghua Yi Xue Za Zhi; 2011 Jul; 91(26):1837-9. PubMed ID: 22093786
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.
Gu X; Jia S; Wei W; Zhang WH
Tumour Biol; 2015 Jul; 36(7):5529-35. PubMed ID: 25682286
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Huober J; Fasching PA; Hanusch C; Rezai M; Eidtmann H; Kittel K; Hilfrich J; Schwedler K; Blohmer JU; Tesch H; Gerber B; Höß C; Kümmel S; Mau C; Jackisch C; Khandan F; Costa SD; Krabisch P; Loibl S; Nekljudova V; Untch M; Minckwitz Gv
Eur J Cancer; 2013 Jul; 49(10):2284-93. PubMed ID: 23541564
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy for breast cancer with weekly nab-paclitaxel followed by epirubicin and cyclophosphamide--results of a case series.
Hahn A; Schlotter CM; Rossmanith WG; Ulmer HU; Staiger HJ; Villena C
In Vivo; 2014; 28(2):235-41. PubMed ID: 24632979
[TBL] [Abstract][Full Text] [Related]
17. [Effects of neoadjuvant chemotherapy of docetaxel combined with and epirubicin or pirarubicin on breast cancer: clinical analysis of 160 cases].
Li XR; Wang JD; Zhang YJ; Kong QL; Ma B; Li J; Zheng YQ; Chen YQ; Jin YC; Li R
Zhonghua Yi Xue Za Zhi; 2009 Jan; 89(2):87-90. PubMed ID: 19489268
[TBL] [Abstract][Full Text] [Related]
18. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
[TBL] [Abstract][Full Text] [Related]
19. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
[TBL] [Abstract][Full Text] [Related]
20. [Docetaxel was effective as neoadjuvant chemotherapy for patients after failure of trans-arterial neoadjuvant chemotherapy with CEF in 2 cases of advanced breast cancer].
Ogawa T; Nagata S; Suzuki H; Onzuka T; Yamanaka N; Kawano R; Yoshida J; Shinohara M; Sumitomo K; Matsuo K; Kuroki S
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1743-5. PubMed ID: 11708023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]